Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area

Try for free

Johnson & Johnson pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Johnson & Johnson, ROE, long-term trends, calculation

Microsoft Excel
ROE = 100 × Net earnings1 ÷ Shareholders’ equity1
Dec 28, 2025 = 100 × ÷
Dec 29, 2024 = 100 × ÷
Dec 31, 2023 = 100 × ÷
Dec 31, 2022 = 100 × ÷
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 29, 2019 = 100 × ÷
Dec 30, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 28, 2014 = 100 × ÷
Dec 29, 2013 = 100 × ÷
Dec 30, 2012 = 100 × ÷
Dec 31, 2011 = 100 × ÷
Dec 31, 2010 = 100 × ÷
Dec 31, 2009 = 100 × ÷
Dec 28, 2008 = 100 × ÷
Dec 30, 2007 = 100 × ÷
Dec 31, 2006 = 100 × ÷
Dec 31, 2005 = 100 × ÷

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions

The return on equity (ROE) exhibited considerable fluctuation over the period examined, ranging from a low of 2.16% to a high of 51.11%. Generally, the ROE demonstrated a period of relative stability in the earlier years, followed by increased volatility and a significant peak in the most recent year.

Initial Period (2005-2008)
From 2005 to 2008, the ROE generally trended upwards, increasing from 27.49% to 30.46%. This indicates improving profitability relative to shareholder investment during this timeframe. A slight dip occurred in 2007, but the overall trajectory remained positive.
Period of Decline and Stabilization (2009-2011)
The years 2009 through 2011 witnessed a substantial decline in ROE, falling from 24.25% in 2009 to 16.94% in 2011. This decrease suggests a weakening in the company’s ability to generate profits from shareholder equity. The ROE appeared to stabilize at a lower level during this period.
Moderate Fluctuations (2012-2017)
From 2012 to 2017, the ROE experienced moderate fluctuations, oscillating between 16.74% and 23.49%. While there was no clear upward or downward trend, the values remained within a relatively narrow range, indicating a degree of consistency in performance. A notable dip to 2.16% occurred in 2017, representing a significant outlier.
Recent Trends (2018-2025)
The period from 2018 to 2025 shows increased volatility. The ROE rose to 25.60% in 2018 and 25.42% in 2019, before decreasing to 23.25% in 2020. A substantial increase was observed in 2021, reaching 28.20%, followed by a decrease to 23.36% in 2022. The ROE peaked at 51.11% in 2023, before decreasing to 19.68% in 2024 and increasing again to 32.87% in 2025. This recent pattern suggests a heightened sensitivity to underlying financial performance and potentially, external factors.

The significant increase in ROE in 2023 warrants further investigation to determine the underlying drivers. The substantial fluctuation in recent years suggests a potential shift in the company’s financial dynamics or increased exposure to external economic conditions. The earlier period of relative stability contrasts sharply with the more recent volatility, indicating a change in the company’s operational or financial characteristics.

Comparison to Competitors

Johnson & Johnson, ROE, long-term trends, comparison to competitors

Microsoft Excel
Johnson & Johnson AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 28, 2025
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Johnson & Johnson, ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Johnson & Johnson Pharmaceuticals, Biotechnology & Life Sciences
Dec 28, 2025
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Industry (Health Care)

Johnson & Johnson, ROE, long-term trends, comparison to industry (health care)

Microsoft Excel
Johnson & Johnson Health Care
Dec 28, 2025
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).